People | September 04, 2024
Enzene appoints new site lead of biologics manufacturing
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
The approval further adds to Biocon’s portfolio of complex drug products
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Subscribe To Our Newsletter & Stay Updated
